OptimizeRx stock gets a higher B. Riley price target

OptimizeRx stock now carries a USD 11.00 B. Riley price target after the firm lifted its previous USD 10.00 target on September 29, 2026, according to GuruFocus. The change puts analyst expectations above the companys latest operating base, while the next earnings update will determine whether growth investments are translating into durable earnings.

Target rises to USD 11.00

GuruFocus reported that B. Riley maintained its Buy rating while raising the target from USD 10.00 to USD 11.00. The USD 1.00 increase represents a 10.00 percent uplift in the target itself, giving the revision a clear quantitative signal even as the stock remains tied to an uneven advertising cycle.

The valuation call is set against a mixed quarterly picture. OptimizeRx generated USD 20.5 million of revenue in Q2 2026, while consolidated net loss was USD 0.7 million and adjusted EBITDA was USD 4.9 million, according to the companys results release carried by FinancialContent.

Guidance sets the operating test

Management reaffirmed fiscal 2026 revenue guidance of USD 95 million to USD 100 million and adjusted EBITDA guidance of USD 21 million to USD 25 million in the same August 12, 2026 release. The Q2 revenue figure therefore represents a quarterly run rate below the midpoint of the full-year range, making second-half execution central to the analyst upgrade.

OpenPath broadens HCP reach

OptimizeRx also announced an integration with The Trade Desks OpenPath platform on September 22, 2026. The companys authenticated point-of-care inventory is expected to become available to advertisers in Q4 2026 across more than 400 electronic health record and e-prescribing systems, reaching 800,000 verified prescribers, according to FinancialContent. That distribution channel could support the companys revenue guidance if pharmaceutical advertisers adopt the inventory in broader programmatic campaigns.

Market value and next reporting date

OptimizeRx had a market capitalization of USD 156.9 million and a 52-week range of USD 4.54 to USD 22.25 as of September 29, 2026. Investing.com lists November 10, 2026 as the next earnings date, giving investors a defined checkpoint for revenue, adjusted EBITDA and the OpenPath rollout.